OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
15
Results
Show all
Save search
Copy query
Show results for
Unknown
(15)
Publication Date
Release Date
2022
(4)
2021
(3)
2023
(2)
2025
(1)
2024
(1)
2016
(1)
2014
(1)
2013
(1)
2012
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Rare and common variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration.
Not available
S-EPMC4189898
|
biostudies-literature
Cite
Identification of a rare coding variant in complement 3 associated with age-related macular degeneration.
Not available
S-EPMC3812337
|
biostudies-literature
Cite
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder.
Not available
S-EPMC3303079
|
biostudies-literature
Cite
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
Not available
S-EPMC4745342
|
biostudies-literature
Cite
Rare coding variation provides insight into the genetic architecture and phenotypic context of autism.
Not available
S-EPMC9653013
|
biostudies-literature
Cite
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788
|
biostudies-literature
Cite
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538
|
biostudies-literature
Cite
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets